Bambusa Therapeutics, Inc. (BBTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of BBTX. The 7-day demo opens the 1M and 3M ranges and puts BBTX on your watchlist.
Start 7-day demoLatest BBTX insider trades
About Bambusa Therapeutics, Inc. (BBTX)
The SEC lists Bambusa Therapeutics, Inc. under CIK 0002044950, in biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector. Its offering priced on 30 October 2026 and it trades on NASDAQ.
BBTX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 750,000 | $12.00M |
| Grant or award | 2 | 1,137,306 | |
| Other acquisition / disposition | 8 | 19,078,804 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
BBTX insider transactions (Form 4)
123 Form 4 filings on record, the earliest from Nov 2, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Salvia Investment GmbH - 10% Owner | Other | Common Stock | 4,769,701 | - footnote F1 | - | |
| Salvia Investment GmbH - 10% Owner | Open-market purchase | Common Stock | 375,000 | $16.00 | $6.00M | |
| Salvia Investment GmbH - 10% Owner | Other | Series Seed Plus Preferred Stock | 3,135,066 | $0.00 | - | |
| Salvia Investment GmbH - 10% Owner | Other | Series A-1 Preferred Stock | 1,473,775 | $0.00 | - | |
| Salvia Investment GmbH - 10% Owner | Other | Series A-2 Preferred Stock | 160,860 | $0.00 | - | |
| ||||||
| Helmut Wolfgang Jeggle - Director | Other | Common Stock | 4,769,701 | - footnote F1 | - | |
| Helmut Wolfgang Jeggle - Director | Open-market purchase | Common Stock | 375,000 | $16.00 | $6.00M | |
| Helmut Wolfgang Jeggle - Director | Other | Series Seed Plus Preferred Stock | 3,135,066 | $0.00 | - | |
| Helmut Wolfgang Jeggle - Director | Other | Series A-1 Preferred Stock | 1,473,775 | $0.00 | - | |
| Helmut Wolfgang Jeggle - Director | Other | Series A-2 Preferred Stock | 160,860 | $0.00 | - | |
| ||||||
| Shanshan Xu - Officer | Grant or award | Stock Option (right to buy) | 379,102 | $0.00 | - | |
| Shanshan Xu - Officer | Grant or award | Restricted Stock Units | 758,204 | $0.00 | - | |
BBTX insider trading FAQ
What is the latest insider trade for BBTX?
Bambusa Therapeutics, Inc. (BBTX) had 3 insider filings in the last 90 days, with the most recent on 2 November 2026. The full record for BBTX runs to 3 Form 4 filings, the earliest from 2 November 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BBTX stock?
2 insider purchases of BBTX were filed in the last 90 days, totaling $12.00M.
How many insiders are selling BBTX stock?
No insider sales of BBTX were filed in the last 90 days.
Where can I see BBTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BBTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
3The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Salvia Investment GmbH view on EDGAR
- - Helmut Wolfgang Jeggle view on EDGAR
- - Shanshan Xu view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where BBTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BBTX with a 7-day demo
- BBTX on your watchlist
- Every BBTX Form 4 filing on record
- Up to 3 months of BBTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
